{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:43:00Z","timestamp":1740148980283,"version":"3.37.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s12325-021-01895-4","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T11:02:37Z","timestamp":1631617357000},"page":"5333-5344","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Health Care Costs in Patients with and without Secondary Hyperparathyroidism\u00a0in Spain"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0228-5084","authenticated-orcid":false,"given":"Enrique","family":"Alonso-Perez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8133-3274","authenticated-orcid":false,"given":"Carles","family":"Forn\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Soro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Valls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1787-7215","authenticated-orcid":false,"given":"Anton-Giulio","family":"Manganelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1343-0184","authenticated-orcid":false,"given":"Jose M.","family":"Valdivielso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,14]]},"reference":[{"key":"1895_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","unstructured":"GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Lond Engl. 2020;395:709\u201333.","journal-title":"Lancet Lond Engl"},{"key":"1895_CR2","doi-asserted-by":"publisher","first-page":"414","DOI":"10.2471\/BLT.17.206441","volume":"96","author":"VA Luyckx","year":"2018","unstructured":"Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018;96:414-422D.","journal-title":"Bull World Health Organ"},{"key":"1895_CR3","doi-asserted-by":"publisher","first-page":"c269","DOI":"10.1159\/000321382","volume":"118","author":"RA Nugent","year":"2011","unstructured":"Nugent RA, Fathima SF, Feigl AB, Chyung D. The burden of chronic kidney disease on developing nations: a 21st century challenge in global health. Nephron Clin Pract. 2011;118:c269\u201377.","journal-title":"Nephron Clin Pract"},{"key":"1895_CR4","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","volume":"382","author":"V Jha","year":"2013","unstructured":"Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260\u201372.","journal-title":"Lancet"},{"key":"1895_CR5","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/ki.2011.368","volume":"80","author":"WG Couser","year":"2011","unstructured":"Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011;80:1258\u201370.","journal-title":"Kidney Int"},{"key":"1895_CR6","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/sj.ki.5002287","volume":"74","author":"WG Goodman","year":"2008","unstructured":"Goodman WG, Quarles LD. Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int. 2008;74:276\u201388.","journal-title":"Kidney Int"},{"key":"1895_CR7","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1038\/ki.2008.64","volume":"73","author":"CP Kovesdy","year":"2008","unstructured":"Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int. 2008;73:1296\u2013302.","journal-title":"Kidney Int"},{"key":"1895_CR8","doi-asserted-by":"crossref","unstructured":"Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol (American Society of Nephrology). 2011;6:913\u201321.","DOI":"10.2215\/CJN.06040710"},{"key":"1895_CR9","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1111\/febs.15300","volume":"287","author":"R Kilav-Levin","year":"2020","unstructured":"Kilav-Levin R, Hassan A, Nechama M, Shilo V, Silver J, Ben-Dov IZ, et al. Post-transcriptional mechanisms regulating parathyroid hormone gene expression in secondary hyperparathyroidism. FEBS J. 2020;287:2903\u201313.","journal-title":"FEBS J"},{"key":"1895_CR10","first-page":"300","volume":"62","author":"JC Bureo","year":"2015","unstructured":"Bureo JC, Ar\u00e9valo JC, Ant\u00f3n J, Adrados G, Jim\u00e9nez Morales JL, Robles NR, et al. Prevalence of secondary hyperparathyroidism in patients with stage 3 and 4 chronic kidney disease seen in internal medicine. Endocrinol Nutr Organo Soc Espanola Endocrinol Nutr. 2015;62:300\u20135.","journal-title":"Endocrinol Nutr Organo Soc Espanola Endocrinol Nutr"},{"issue":"42","key":"1895_CR11","first-page":"1050","volume":"2003","author":"MJ Sarnak","year":"1979","unstructured":"Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertens Dallas Tex. 1979;2003(42):1050\u201365.","journal-title":"Hypertens Dallas Tex"},{"key":"1895_CR12","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1001\/jama.2011.308","volume":"305","author":"SC Palmer","year":"2011","unstructured":"Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011;305:1119\u201327.","journal-title":"JAMA"},{"key":"1895_CR13","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12882-020-02088-x","volume":"21","author":"C Kato","year":"2020","unstructured":"Kato C, Fujii N, Miyakoshi C, Asada S, Onishi Y, Fukuma S, et al. Changes in 3-month mineral and bone disorder patterns were associated with all-cause mortality in prevalent hemodialysis patients with secondary hyperparathyroidism. BMC Nephrol. 2020;21:432.","journal-title":"BMC Nephrol"},{"key":"1895_CR14","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1681\/ASN.2013060632","volume":"24","author":"M Allon","year":"2013","unstructured":"Allon M. Evidence-based cardiology in hemodialysis patients. J Am Soc Nephrol JASN. 2013;24:1934\u201343.","journal-title":"J Am Soc Nephrol JASN"},{"key":"1895_CR15","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/1472-6963-13-248","volume":"13","author":"V Belozeroff","year":"2013","unstructured":"Belozeroff V, Cooper K, Hess G, Chang C-L. Healthcare use and costs before and after parathyroidectomy in patients on dialysis. BMC Health Serv Res. 2013;13:248.","journal-title":"BMC Health Serv Res"},{"key":"1895_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12882-015-0054-0","volume":"16","author":"S Kent","year":"2015","unstructured":"Kent S, Schlackow I, Lozano-K\u00fchne J, Reith C, Emberson J, Haynes R, et al. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease? BMC Nephrol. 2015;16:65.","journal-title":"BMC Nephrol"},{"key":"1895_CR17","first-page":"840","volume":"147","author":"SC Palmer","year":"2007","unstructured":"Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GFM. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med (American College of Physicians). 2007;147:840\u201353.","journal-title":"Ann Intern Med (American College of Physicians)."},{"key":"1895_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1517\/14728214.2015.1018177","volume":"20","author":"M Cozzolino","year":"2015","unstructured":"Cozzolino M, Tomlinson J, Walsh L, Bellasi A. Emerging drugs for secondary hyperparathyroidism. Expert Opin Emerg Drugs (Taylor & Francis). 2015;20:197\u2013208.","journal-title":"Expert Opin Emerg Drugs (Taylor & Francis)."},{"key":"1895_CR19","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/pds.2183","volume":"20","author":"RD Kilpatrick","year":"2011","unstructured":"Kilpatrick RD, Danese MD, Belozeroff V, Smirnakis K, Goodman WG, Rothman KJ. The association of vitamin D use with hypercalcemia and hyperphosphatemia in hemodialysis patients: a case\u2013crossover study. Pharmacoepidemiol Drug Saf. 2011;20:914\u201321.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1895_CR20","doi-asserted-by":"publisher","first-page":"c54","DOI":"10.1159\/000228076","volume":"113","author":"GT Schumock","year":"2009","unstructured":"Schumock GT, Andress DL, Marx SE, Sterz R, Joyce AT, Kalantar-Zadeh K. Association of secondary hyperparathyroidism with CKD progression, health care costs and survival in diabetic predialysis CKD patients. Nephron Clin Pract. 2009;113:c54-61.","journal-title":"Nephron Clin Pract"},{"key":"1895_CR21","first-page":"e24","volume":"5","author":"A Lee","year":"2013","unstructured":"Lee A, Belozeroff V, Song X, Diakun D, Goodman W. Costs of treatment and clinical events for secondary hyperparathyroidism. Am J Pharm Benefits. 2013;5:e24-35.","journal-title":"Am J Pharm Benefits"},{"key":"1895_CR22","doi-asserted-by":"crossref","unstructured":"Roggeri A, Conte F, Rossi C, Cozzolino M, Zocchetti C, Roggeri DP. Cinacalcet adherence in dialysis patients with secondary hyperparathyroidism in Lombardy region: clinical implications and costs. Drugs Context (internet). 2020;9. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7111129\/. Accessed 24 Jan 2021.","DOI":"10.7573\/dic.2020-1-1"},{"key":"1895_CR23","first-page":"1","volume":"8","author":"DP Roggeri","year":"2015","unstructured":"Roggeri DP, Cozzolino M, Mazzaferro S, Brancaccio D, Paoletti E, Roggeri A, et al. Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study. Int J Nephrol Renov Dis. 2015;8:1\u20136.","journal-title":"Int J Nephrol Renov Dis"},{"key":"1895_CR24","first-page":"397","volume":"13","author":"MS Joy","year":"2007","unstructured":"Joy MS, Karagiannis PC, Peyerl FW. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm JMCP. 2007;13:397\u2013411.","journal-title":"J Manag Care Pharm JMCP"},{"key":"1895_CR25","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1186\/s12913-016-1671-4","volume":"16","author":"L Manjarres","year":"2016","unstructured":"Manjarres L, Sanchez P, Cabezas MC, Fornasini M, Freire V, Albert A. Budget impact of secondary hyperparathyroidism treatment in chronic kidney disease in an Ecuadorian social security hospital. BMC Health Serv Res. 2016;16:443.","journal-title":"BMC Health Serv Res"},{"key":"1895_CR26","doi-asserted-by":"publisher","first-page":"c159","DOI":"10.1159\/000099006","volume":"105","author":"S Khan","year":"2007","unstructured":"Khan S. Secondary hyperparathyroidism is associated with higher cost of care among chronic kidney disease patients with cardiovascular comorbidities. Nephron Clin Pract. 2007;105:c159-164.","journal-title":"Nephron Clin Pract"},{"key":"1895_CR27","doi-asserted-by":"crossref","unstructured":"Junyent M, Mart\u00ednez M, Borr\u00e0s M, Coll B, Valdivielso JM, Vidal T, et al. Predicting cardiovascular disease morbidity and mortality in chronic kidney disease in Spain. The rationale and design of NEFRONA: a prospective, multicenter, observational cohort study. BMC Nephrol. 2010;11:14.","DOI":"10.1186\/1471-2369-11-14"},{"key":"1895_CR28","first-page":"119","volume":"30","author":"M Junyent","year":"2010","unstructured":"Junyent M, Mart\u00ednez M, Borr\u00e1s M, Bertriu A, Coll B, Craver L, et al. Usefulness of imaging techniques and novel biomarkers in the prediction of cardiovascular risk in patients with chronic kidney disease in Spain: the NEFRONA project. Nefrol Public Soc Espanola Nefrol. 2010;30:119\u201326.","journal-title":"Nefrol Public Soc Espanola Nefrol"},{"key":"1895_CR29","first-page":"S1","volume":"42","author":"National Kidney Foundation","year":"2003","unstructured":"National Kidney Foundation. K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis Off J Natl Kidney Found. 2003;42:S1-201.","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"1895_CR30","first-page":"1","volume":"33","author":"E Bellorin-Font","year":"2013","unstructured":"Bellorin-Font E, Ambrosoni P, Carlini RG, Carvalho AB, Correa-Rotter R, Cueto-Manzano A, et al. Gu\u00edas de pr\u00e1ctica cl\u00ednica para la prevenci\u00f3n, diagn\u00f3stico, evaluaci\u00f3n y tratamiento de los trastornos minerales y \u00f3seos en la enfermedad renal cr\u00f3nica (TMO-ERC) en adultos. Nefrol Madr Soc Espa\u00f1ola Nefrol. 2013;33:1\u201328.","journal-title":"Nefrol Madr Soc Espa\u00f1ola Nefrol"},{"key":"1895_CR31","first-page":"915","volume":"12","author":"MJ Moro-\u00c1lvarez","year":"2016","unstructured":"Moro-\u00c1lvarez MJ, Mu\u00f1oz RN. Protocolo de diagn\u00f3stico y tratamiento del hiperparatiroidismo primario y secundario. Med-Program Form M\u00e9d Contin Acreditado. 2016;12:915\u20139.","journal-title":"Med-Program Form M\u00e9d Contin Acreditado"},{"key":"1895_CR32","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Ortiz ME, Rodr\u00edguez M. Recent advances in understanding and managing secondary hyperparathyroidism in chronic kidney disease. F1000Research (internet). 2020. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7463297\/. Accessed 26 Jan 2021.","DOI":"10.12688\/f1000research.22636.1"},{"key":"1895_CR33","first-page":"51","volume":"29","author":"MT \u00c1lvarez Gonzalez","year":"2009","unstructured":"\u00c1lvarez Gonzalez MT. Manejo del hiperparatiroidismo secundario con los f\u00e1rmacos actuales. Nefrolog\u00eda (Elsevier). 2009;29:51\u20136.","journal-title":"Nefrolog\u00eda (Elsevier)"},{"key":"1895_CR34","first-page":"3","volume":"31","author":"J-V Torregrosa","year":"2011","unstructured":"Torregrosa J-V, Bover J, Cannata And\u00eda J, Lorenzo V, de Francisco ALM, Mart\u00ednez I, et al. Spanish Society of Nephrology recommendations for controlling mineral and bone disorders in chronic kidney disease patients (S.E.N.-M.B.D.). Nefrol Engl Ed (Elsevier). 2011;31:3\u201332.","journal-title":"Nefrol Engl Ed (Elsevier)."},{"key":"1895_CR35","unstructured":"BOT PLUS\u2014Web de Portalfarma. https:\/\/www.portalfarma.com\/inicio\/botplus20\/Paginas\/Bot-PLUS-2-0.aspx. https:\/\/www.portalfarma.com\/inicio\/botplus20\/Paginas\/Bot-PLUS-2-0.aspx. Accessed 25 Jan 2021."},{"key":"1895_CR36","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s40258-014-0097-6","volume":"12","author":"J Puig-Junoy","year":"2014","unstructured":"Puig-Junoy J, Rodr\u00edguez-Feijo\u00f3 S, Lopez-Valcarcel BG. Paying for formerly free medicines in Spain after 1 year of co-payment: changes in the number of dispensed prescriptions. Appl Health Econ Health Policy. 2014;12:279\u201387.","journal-title":"Appl Health Econ Health Policy"},{"key":"1895_CR37","unstructured":"Ministerio de Sanidad, Consumo y Bienestar Social-statical site of the NHS-hospital discharge records in the national health system. CMBD. https:\/\/www.mscbs.gob.es\/en\/estadEstudios\/estadisticas\/cmbdhome.htm. https:\/\/www.mscbs.gob.es\/en\/estadEstudios\/estadisticas\/cmbdhome.htm. Accessed 21 Jan 2021."},{"key":"1895_CR38","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1681\/ASN.2014070714","volume":"26","author":"S Thompson","year":"2015","unstructured":"Thompson S, James M, Wiebe N, Hemmelgarn B, Manns B, Klarenbach S, et al. Cause of death in patients with reduced kidney function. J Am Soc Nephrol JASN. 2015;26:2504\u201311.","journal-title":"J Am Soc Nephrol JASN"},{"key":"1895_CR39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/kisup.2015.2","volume":"5","author":"AJ Collins","year":"2015","unstructured":"Collins AJ, Foley RN, Gilbertson DT, Chen S-C. United States renal data system public health surveillance of chronic kidney disease and end-stage renal disease. Kidney Int Suppl. 2015;5:2\u20137.","journal-title":"Kidney Int Suppl"},{"key":"1895_CR40","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.18203\/2320-6012.ijrms20193144","volume":"7","author":"CL Dayma","year":"2019","unstructured":"Dayma CL, Ajmera D, Jelia SC, Jain P. Study of prevalence of secondary hyperparathyroidism in chronic renal failure in Hadoti region. Int J Res Med Sci. 2019;7:2903\u20138.","journal-title":"Int J Res Med Sci"},{"key":"1895_CR41","first-page":"657","volume":"33","author":"WG Douthat","year":"2013","unstructured":"Douthat WG, Castellano M, Berenguer L, Guzm\u00e1n MA, de Arteaga J, Chiurchiu CR, et al. High prevalence of secondary hyperparathyroidism in chronic kidney disease patients on dialysis in Argentina. Nefrol Public Soc Espanola Nefrol. 2013;33:657\u201366.","journal-title":"Nefrol Public Soc Espanola Nefrol"},{"key":"1895_CR42","unstructured":"Junaid Z, Patel J. Cinacalcet. StatPearls (internet). Treasure Island (FL): StatPearls Publishing; 2021. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557658\/. Accessed 28 Mar 2021."},{"key":"1895_CR43","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1159\/000223800","volume":"163","author":"JM Valdivielso","year":"2009","unstructured":"Valdivielso JM. The physiology of vitamin D receptor activation. Contrib Nephrol. 2009;163:206\u201312.","journal-title":"Contrib Nephrol"},{"key":"1895_CR44","doi-asserted-by":"crossref","unstructured":"Alvarez-Sab\u00edn J, Quintana M, Masjuan J, Oliva-Moreno J, Mar J, Gonzalez-Rojas N, et al. Economic impact of patients admitted to stroke units in Spain. Eur J Health Econ. (Springer & Deutsche Gesellschaft f\u00fcr Gesundheits\u00f6konomie (DGG\u00d6)). 2017;18:449\u201358.","DOI":"10.1007\/s10198-016-0799-9"},{"key":"1895_CR45","unstructured":"Red Espa\u00f1ola de Costes Hospitalarios. An\u00e0lisi del cost de l\u2019atenci\u00f3 hospital\u00e0ria. Hospitals incorporats a la Xarxa de costos hospitalaris (RECH). http:\/\/catsalut.gencat.cat\/web\/.content\/minisite\/catsalut\/coneix_catsalut\/informacio-economica\/documents\/analisi-del-cost-de-latencio-hospitalaria.Hospitals-incorporats-a-la-Xarxa-de-costos-hospitalaris-RECH.pdf. http:\/\/catsalut.gencat.cat\/web\/.content\/minisite\/catsalut\/coneix_catsalut\/informacio-economica\/documents\/analisi-del-cost-de-latencio-hospitalaria.Hospitals-incorporats-a-la-Xarxa-de-costos-hospitalaris-RECH.pdf. Accessesed 3 Feb 2021."},{"key":"1895_CR46","doi-asserted-by":"publisher","unstructured":"Xu Y, Evans M, Soro M, Barany P, Carrero JJ. Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease. Clin Kidney J (internet). 2021. https:\/\/doi.org\/10.1093\/ckj\/sfab006. Accessed 26 Feb 2021.","DOI":"10.1093\/ckj\/sfab006"},{"key":"1895_CR47","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00774-009-0048-8","volume":"27","author":"DH Smith","year":"2009","unstructured":"Smith DH, Johnson ES, Thorp ML, Yang X, Neil N. Hyperparathyroidism in chronic kidney disease: a retrospective cohort study of costs and outcomes. J Bone Miner Metab. 2009;27:287\u201394.","journal-title":"J Bone Miner Metab"},{"key":"1895_CR48","doi-asserted-by":"publisher","unstructured":"Bozic M, Diaz-Tocados JM, Bermudez-Lopez M, Forn\u00e9 C, Martinez C, Fernandez E, et al. Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort. Nephrol Dial Transplant (internet). 2021. https:\/\/doi.org\/10.1093\/ndt\/gfab184. Accessed 14 Jul 2021.","DOI":"10.1093\/ndt\/gfab184"},{"key":"1895_CR49","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","volume":"92","author":"M Ketteler","year":"2017","unstructured":"Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what\u2019s changed and why it matters. Kidney Int. 2017;92:26\u201336.","journal-title":"Kidney Int"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01895-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01895-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01895-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T09:06:43Z","timestamp":1632820003000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01895-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,14]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1895"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01895-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2021,9,14]]},"assertion":[{"value":"14 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}